Swiss drug major Roche reported Wednesday that Group sales increased by 6% on a currency-adjusted basis to 44.98 billion Swiss francs ($51.8 billion) from last year’s 44.05 billion francs. The company noted that strong demand for novel medicines like eye drug Vabysmo and multiple sclerosis treatment Ocrevus, as well as diagnostic products, more than offset the anticipated decline in Covid-19-related sales and margin erosion due to generics. The Pharmaceuticals Division’s sales increased 7% from last year to 34.26 billion francs. The base business sales, excluding Covid-19 products, grew 9%. In…